Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

NCT04361903 · clinicaltrials.gov ↗

UNKNOWN

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG: Ruxolitinib Oral Tablet

Sponsor

Azienda USL Toscana Nord Ovest

Collaborators

[object Object]
[object Object]
[object Object]